1. , , , et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349:589–93.
2. , , , et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50:398–402.
3. , , , et al. Intravenous immunoglobulin G reduces MRI activity in relapsing remitting multiple sclerosis. Neurology 1998; 50:1273–81.
4. , , , et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878–86.
5. , , , et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364:1149–56.
6. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227–8.
, , , et al
. Determinants of human B cell migration across brain endothelial cells
. J Immunol 2003
8. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59:802–8.
9. , , , et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172:7144–53.
10. , , , et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004; 127:1370–8.
11. , , , et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007; 13:935–43.
12. , , , et al. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol 2011; 232:136–44.
13. , , , et al. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 2010; 221:136–45.
14. , , , , Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005; 4:567–75.
15. , , , et al. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Mult Scler 2009; 15:959–64.
16. , B cell immunobiology in disease – evolving concepts from the clinic. Annual Rev Immunol 2006; 24:467–496.
17. , , , et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178:6092–9.
18. , , , Characterization of a human B lymphocyte–specific antigen. J Immunol 1980; 125:1678–85.
19. , , , The biology of CD20 and its potential as a target for mAb therapy. In Curr Dir Autoimmun vol 8:140–174, Karger: Basel, 2005.
20. , , The anti-tumor effect of monoclonal anti CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 1996; 88(Suppl 1):637a.
21. , , , et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949–54.
22. , , , et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21:1746–51.
23. , , , et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:1–67.
24. , , B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 2002; 30:824–8.
25. , , Clinical outcome in 22 patients with rheumatoid arthritis treated with B-cell depletion. Ann Rheum Dis 2002; 61:883–8.
26. , , , et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572–81.
27. , , , et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46:2673–77.
28. SLE-rituximab in lupus. Arthritis Res Ther 2003; 5:157–9.
29. , , , et al. Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximab. Leuk Lymphoma 2003; 44:561–2.
30. , , , et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87:189–95.
31. , , , et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74:485–9.
32. , , , CSF B cell over-expansion in paraneoplastic opsoclonus-myoclonus syndrome: effect of rituximab, an anti–B-cell monoclonal antibody. Neurology 2003 60(Suppl 1):A395.
33. , , , et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180:63–70.
34. , , , et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010; 74:1860–7.
35. , , , et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63:395–400.
36. , , , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676–88.
37. , , , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460–71.
38. , , Rituximab: active treatment of central nervous system involvement by non-Hodgkin lymphoma? Ann Oncol 2000; 11:374–5.
39. , , , et al. Abnormal B cell cytokine responses: a trigger of T-cell-mediated disease in MS? Ann Neurol 2010; 67:452–61.
40. , , , et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008; 58:2652–61.
41. , , , et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: results of a phase II randomized placebo-controlled multicenter trial. Mult Scler 2010; 16:S114.
42. , , , et al. Magnetic resonance imaging efficacy of ofatumumab in relapsing-remitting multiple sclerosis – 24-week results of a phase II study. Mult Scler 2010; 16:S136.
43. , , , et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48:2146–54.
44. , , , et al. Changes in B and T lymphocytes and chemokines with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67:707–14.
45. , , , et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62:258–64.
46. , , , Rituximab in a patient with multiple sclerosis–effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008; 117:399–403.
47. , , et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005; 62:1620–3.
48. , , Intact B-cell activity is essential for complete expression of experimental allergic encephalomyelitis in Lewis rats. Cell Immunol 1982; 72:360–6.
49. , , Immunoglobulin deficient rats as donors and recipients of effector cells of allergic encephalomyelitis. J Neuroimmunol 1986; 11:93–103.
50. , , , B-cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 1999; 29:3432–9.
51. , , , et al. Antibody facilitation of multiple sclerosis-like lesions in nonhuman primate. J Clin Invest 1995; 96:2966–74.
52. , , , A monoclonal antibody against myelin oligodendroctye glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987; 139:4016–20.
53. , , , et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol 2003; 21:1033–9.
54. Immunoglobulin-containing cells in multiple sclerosis plaques. Lancet 1977;ii:478–80.
55. , , , Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5:170–5.
56. , , Critical role of antigen-specific antibody in EAE induced by recombinant MOG. Eur J Immunol 2002; 32:1905–13.
57. , Do myelin antibodies predict the diagnosis of multiple sclerosis? N Engl J Med 2003; 349:107–9.
58. , , , et al. Retargeting T Cell-mediated inflammation: a new perspective on autoantibody action. J Immunol 2000; 164:5251–7.
59. , , Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46:538–45.
60. , , , et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol 2003; 145:139–47.
61. , , , et al. Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol 2004; 173:6981–92.
62. Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS. J Neurol 1979; 221:39–51.
63. , , , et al. Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. Eur J Neurol 2002; 9:243–51.
64. , , The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol 2001; 21:81–92.
65. , , , et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998; 102:1045–50.
66. , , , et al. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998; 43:236–43.
67. , , , et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999; 163:5133–44.
68. , , , et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000; 164:2782–9.
69. , , et al. Short lived plasma blasts are the main B cell effector subset during the course of MS. Brain 2005; 128:1667–76.
70. , Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA and IgM in multiple sclerosis. J Exp Med 1986; 163:41–53.
71. , , , Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 15:227–31.
72. , , , et al. Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995; 1:150–5.
73. , , , et al. Cerebrospinal fluid cytologic findings in multiple sclerosis. A comparison between patient subgroups. Acta Cytol 2001; 45:51–9.
74. , , , et al. Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol Scand 2002; 105:158–63.
75. , , , et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003; 53:222–6.
76. , Human cerebrospinal Fluid immunology. In: , , eds. Cerebrospinal Fluid, Martinus Nyhoff: Amsterdam, 1989:179–226.
77. , , B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001; 122:1–14.
78. , , , et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47:707–17.
79. , , , et al. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998; 43:465–71.
80. , , , The application of multifactorial cluster analysis in the staging of plaques in early MS. Identification and characterization of the primary demyelinating lesions. Brain 1997; 120:1461–83.
81. , , , et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005; 175:1974–82.
82. , , , et al. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology 1987; 37:1515–19.
83. , , , Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol 1990; 27:132–6.
84. , , , et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999; 122:2047–56.
85. , , , et al. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 2001; 7:285–9.
86. , , , et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349:139–45.
87. , , , et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11:492–4.
88. , , , et al. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol. 2010; 223:92–9.
89. , , Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44:980–3.
90. , , , et al. Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler 1999; 5:379–88.
91. , , , et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005; 116:453–9.
92. , , , et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 2003; 136:140–8.
93. , , Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004; 127:269–79.
94. , , , et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005; 116:453–9.
95. , , , et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103:19057–62.
96. , , , et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103:2280–5.
97. , , , et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13:211–17.
98. , , , et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183:4067–76.
99. , , , et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66:833–42.
100. , , , et al. Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. Mult Scler 2010; 16:1189–92.
101. , , , et al. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med 1994; 180:1295–306.
102. , , , et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189:1639–48.
103. , , , et al. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 1998; 161:1163–8.
104. B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J Immunol 1999; 162:5695–703.
105. , , Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997; 99:2664–71.
106. , , , et al. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol 2001; 167:5669–77.
107. Receptor-mediated antigen uptake and its effect on antigen presentation to class II restricted T lymphocytes. Annu Rev Immunol 1990; 8:773–93.
108. , Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80:695–705.
109. , , , , Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118:3420–30.
110. , , , et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010; 68:369–83.
111. , , , et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 2004; 101:11064–9.
112. , , Unveiling the enigma of the CNS as a B-cell fostering environment. Trends Immunol 2005; 26:254–9.
113. , , , et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130:1089–104.
114. , , , Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005; 8:25–54.
115. , , Distinct profiles of human B cell effector cytokines: A role in immune regulation? J Immunol 2004; 172:3422–7.
116. , , , , . Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996; 184:2271–8.
117. , , , et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3:944–50.
118. , , Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 2008; 64:187–99.
119. , , , et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14:164–74.
120. , , , et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum 2005; 52:1773–84.
121. , , Ectopic lymphoid organogenesis: a fast track for autoimmunity. Am J Pathol 2001; 159:787–93.
122. , , , et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170:4497–505.
123. , , , et al. Analyses of all matrix metalloproteinase members in leuckocytes: monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003; 126:2738–49.
124. , , , et al. Epstein–Barr virus antibodies and risk of multiple sclerosis: a prospective study. J Am Med Assoc 2001; 286:3083–8.
125. , , , et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3:940–3.
126. , , , , Epstein-Barr virus in pediatric multiple sclerosis. J Am Med Assoc 2004; 291:1875–9.
127. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003; 24:584–8.
128. , , , et al. Clinical features and viral serologies in children with multiple sclerosis: results of a multinational cohort study. Lancet Neurology 2007; 6:773–81.
129. , EBV and brain matter(s)? Neurology 2010; 74:1092–5.